BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 8
• 9
• 10
• 11
• 14
• 15
• 16
• 17
• 18
• 21
• 22
• 23
• 24
• 25
• 28
• 29
• 30

• Business

  INSYS Therapeutics In-Licenses Cannabinoid Inhalation Technology

  September 28, 2015

   · 

  5 min read
• Drug Development

  OncoGenex Presents Additional Phase 3 SYNERGY Analyses Showing Custirsen Significantly Reduced Serum Clusterin Levels In Metastatic Prostate Cancer Patients; Low Levels Correlate With Improved Survival In Those At Increased Risk For Poor Outcomes

  September 28, 2015

   · 

  9 min read
• Drug Development

  Novartis AG Drug Afinitor Significantly Improves Progression-Free Survival In Advanced Nonfunctional Gastrointestinal And Lung NET

  September 28, 2015

   · 

  11 min read
• Biotech Bay

  Thoratec Release: HeartMate 3 CE Mark Trial Meets Primary Endpoint

  September 28, 2015

   · 

  6 min read
• Policy

  FDA Grants Eisai Inc.'s sNDA For Eribulin Priority Review Designation For The Potential Treatment Of Advanced Soft Tissue Sarcoma

  September 28, 2015

   · 

  6 min read
• Drug Development

  VBL Therapeutics Reports Full Phase 2 Data From Clinical Trial Of VB-111 In Recurrent Glioblastoma (rGBM) At The ECC 2015 Conference, Meeting The Primary Endpoint Of Statistically-Significant Increase In Overall Survival

  September 28, 2015

   · 

  7 min read
• Drug Development

  NewLink Genetics Announces Promising Phase 1b Data From The Combination Of Indoximod And Ipilimumab In Melanoma At European Cancer Congress 2015 (ECC)

  September 28, 2015

   · 

  4 min read
• Genetown

  Boston Scientific Release: Eluvia Drug-eluting Vascular Stent System Demonstrates 12-month Primary Patency Of 96.1 Percent

  September 28, 2015

   · 

  6 min read
• Biotech Bay

  Genomic Health, Inc. Release: TAILORx Trial Finds 99 Percent Of Women With Low Oncotype DX Recurrence Score Are Free Of Breast Cancer Recurrence After Five Years Of Hormone Therapy Alone

  September 28, 2015

   · 

  8 min read
• Biotech Beach

  GenomeDx Biosciences Secures Financing From CRG

  September 28, 2015

   · 

  3 min read